siRNA Gene Silencing – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

siRNA, or short interfering RNA, is a non-coding RNA sequence that can inhibit gene expression, making it a key component in various therapeutic innovations. While the discovery of siRNA for targeted therapies dates back over a decade, current efforts are focused on improving stability and targeted delivery. The gene silencing capabilities of siRNA have led to its widespread use in novel therapies, with a significant number of patents set to expire in the near future.
Recent patent analysis shows a growing trend in siRNA innovation, with a particular focus on metabolic diseases, infectious diseases, neurological diseases, and cardiovascular diseases. The majority of patent activity is driven by universities and research institutions, with over 100 new entities filing patents in the past two years.
The innovation landscape is primarily dominated by companies in Southeast Asia, particularly in China, Japan, and South Korea. Among publicly listed companies, leaders in siRNA gene silencing include Alnylam, Thermo Fisher (Revvity/Dharmacon), and Sirnaomics. Additionally, there are over 50 startups in this space, with Chinese companies like Suzhou Ribo Life Sciences and Gangzhou Ribo Bio leading the way.
In the drug landscape, there are currently 799 siRNA gene silencing drugs in development, with a focus on oncology and metabolic disorders therapies. The most common route of administration is subcutaneous, and major players like Alnylam Pharmaceuticals Inc and Sirnaomics Ltd are leading the way in drug development, particularly in Phase I and Phase II trials.
Alnylam Pharmaceuticals Inc leads the way in clinical trials for siRNA gene silencing drugs, with 79 trials, followed by Arrowhead Pharmaceuticals Inc with 48 trials. Metabolic disorders trials are the most prevalent, with Hepatitis B being the top indication.
In terms of deals, there have been 334 deals totaling US$107 billion in the siRNA gene silencing sector. The United States and Ireland stand out with two major M&A deals worth $54.9 billion. The highest deal volume was observed in 2023, while the highest deal value was seen in 2020. The slight decline in 2021, followed by a slight increase in 2022, may indicate market adjustments and strategic consolidations. The United States is the major geography for deals, with a deal value of US$54.9 billion and the highest deal volume since 2020.

Scope

Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.

Key player: This represents a sample list of key players in each use case highlighted in the report.

Startups: This represents a sample list of emerging starups in each use case highlighted in the report.

University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

1. siRNA Gene Silencing report is a high-impact innovation area in the Pharma industry, with a growing number of patents being filed and a focus on new indications such as Oncology and Infectious diseases.

2. Big pharma companies like Merck and co dominate the patent activity in Membrane protein targeting and modulation with a dip in new companies filing patents in recent years.

3. Competitive intelligence shows that Alnylam leads in terms of portfolio size followed by Hanmi Science and Eli Lilly&Co. are among the leaders with strong innovation portfolios in siRNA gene silencing.

4. Startups like Suzhou Ribo Life Sciences, Ractigen and Curigin are leading in terms of innovation impact and focus in the siRNA gene silencing.

5. The drug landscape for siRNA gene silencing is dominated by innovator drugs, with a focus on Oncology and Metabolic disorders, and major players like Alnylam Pharmaceuticals Inc and sirnaomics Ltd leading in drug development.

6. Clinical trials in siRNA gene silencing are dominated by Metabolic disorders trials, with the Alnylam Pharmaceuticals Inc leading in the number of trials.

Reasons to Buy

Drive Innovation with Our siRNA Gene Silencing Report:

Emerging technologies like siRNA gene silencing are revolutionizing healthcare, and staying ahead requires actionable insights. Our report offers comprehensive analysis of patents, drug pipelines, clinical trials, and market dynamics, empowering strategic planning and R&D decisions. Stay informed on regulatory changes and clinical advancements critical for navigating the evolving healthcare landscape. Identify investment opportunities through detailed financial deal and funding trend analyses. Whether you're a pharmaceutical leader, biotech innovator, or academic researcher, this report delivers essential competitive intelligence to guide data-driven decisions and ensure you remain at the forefront of gene silencing innovation.

Alnylam Pharmaceuticals Inc
Sirnaomics Ltd
Novo Nordisk AS
Suzhou Ribo Life Sciences Co Ltd
Shanghai Argo Pharmaceutical Co Ltd
OliX Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Quark Pharmaceuticals Inc
Silence Therapeutics Plc
Phio Pharmaceuticals Corp
Arbutus Biopharma Corp
Argonaute RNA Ltd
Sanegene Bio USA Inc
Rona Therapeutics Inc
siRNAgen Therapeutics Corp
e-Therapeutics Plc
Sylentis SAU Risen(Shanghai) Pharma Tech Co Ltd
Sirius Therapeutics Inc
Novartis AG
Adhera Therapeutics Inc
Alys Pharmaceuticals Inc
Eli Lilly and Co
Synerk Inc
Jivana Biotechnology Inc

Table of Contents

Table of Contents

1. Innovation Insights

1.1 Innovation radar

1.2 Innovation s-curve

1.3 Innovation deep dive

1.4 Innovation deep dive – trending indications

1.5 Top companies Based on portfolio strength and temporal indicators

2. Competitive Insights

2.1 Key innovation leaders – big pharma

2.2.Key innovators – startups and small biotech

2.3 Key innovations – Universities and research institutions

2.4 Most cited patents

2.5 Insights from AI hub

3.Market Insights

3.1 Drugs

3.1.1 Key Players

3.1.2 Route of administration & drug type

3.1.3 Top therapy area & indication

3.2 Clinical Trials

3.2.1 Key Sponsors

3.2.2 Key development stages

3.3 Deals

3.3.1. Key Acquirers

3.3.2 Deal type distribution

3.3.3 Geographical distribution

siRNA Gene Silencing – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals standard reports
Currency USD
$2,499

Can be used by individual purchaser only

$7,497

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

siRNA Gene Silencing – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at siRNA Gene Silencing – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals in real time.

  • Access a live siRNA Gene Silencing – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.